The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment

AIDS Research and Therapy

Volumn 8, Issue , 2011, Pages

  Sinha, Sanjeev ^a   Dhooria, Sahajal ^a   Kumar, Sanjiv ^a   Shah, Nipam ^a   Velpandian, T ^a   Ravi, A K ^a   Kumar, Narendra ^a   Ahmad, Hafeez ^a   Bhargwa, Akshat ^a   Chug, Karan ^a   Bumma, Naresh ^a   Chandrashekhar, Rahul ^a   Ekka, Meera ^a   Sreenivas, Vishnu ^a   Sharma, Surendra K ^a   Samantaray, J C ^a   Mitsuyasu, Ronald ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human immunodeficiency virus (hiv); Nevirapine; Rifampicin; Tuberculosis (tb)

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUROPATHY; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 80055106352     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-8-41     Document Type: Article

References (23)

1. UNAIDS 2008 report on the global AIDS epidemic. 2011, , http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp
2. WHO report 2008. Global tuberculosis control- surveillance, planning, financing. 2011, , http://www.who.int/tb/publications/global_report/2008/download_centre/en/index.html
3. Technical report on HIV estimation, 2006. National AIDS Control Organisation, Ministry of Health and Family Welfare, Government of India 2011, , http://www.nacoonline.org/Quick_Links/HIV_Data/
4. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents including Post-exposure Prophylaxis 2009. National AIDS Control Organization, Ministry of Health & Family Welfare, Government of India 2011, Therapy Guidelines for HIV infected Adults., http://upaidscontrol.up.nic.in/ART%20Guidelines%20for%20HIV-Infected%20Adults%20and%20Adolescents%20Including%20Post-exposure.pdf
5. Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, Mayer KH. The safety, tolerability and effectiveness of generic antiretroviral regimens for HIV-infected patients in south India. AIDS 2003, 17:2267-2269.
6. Ghate MV, Divekar AD, Risbud AR, Thakar MR, Brahme RG, Mehendale SM. Changing trends in clinical presentations in referred human immunodeficiency virus infected persons in Pune, India. J of Assoc of Physicians of India 2002, 50:671-673.
7. Swaminathan S, Sangeetha M, Arunkumar N, Menno AP, Thomas B, Shibi P, Ponnuraja Rajasekar S. Pulmonary tuberculosis in HIV positive individuals: preliminary report on clinical features and response to treatment. Ind J Tub 2002, 49:189-193.
8. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001, 164:7-12.
9. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naBve patients in India who are co-infected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004, 37:1166-1169.
10. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. World Health Organization 2011, , http://www.who.int/hiv/pub/arv/adult/en/index.html
11. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K. Plasma nevirapine concentrations and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006, 43:253-255.
12. Sathia L, Obiorah I, Taylor G, Kon O, O'Donoghue M, Gibbins S, Walsh J, Winston A. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients. AIDS Res Hum Retroviruses 2008, 24:897-901.
13. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaew K, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K, Burger DM. Nevirapine plasma concentrations and concomitant use of rifampin in patients co-infected with HIV-1 and tuberculosis. Antivir Ther 2005, 10:937-943.
14. Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008, 61:389-393.
15. Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, Sathishnarayan S, Raja K, Kumaraswami V, Swaminathan S. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006, 42:36-41.
16. Revised national tuberculosis control programme. Technical and operational guidelines for tuberculosis control 2005 2011, , http://www.tbcindia.org/pdfs/Linking%20HIV-Infected%20TB%20Patients%20to%20Cotrimoxazole%20prophylaxis%20and%20Anti%20retroviral%20treatment%20in%20India.pdf
17. Thiebaut R, Jacqmin-Gadda H, Walker S. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion. Journal of HIV medicine 2006, 7(1):1-9.
18. Zaragoza-Macias E, Cosco D, Nguyen ML, Del Rio C, Lennox J. Predictors of success with highly active antiretroviral therapy in an antiretroviral-naïve urban population. AIDS Res Hum Retroviruses 2010, 26(2):133-38.
19. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, Thior I, Avalos A, Moffat HJ, Mboya JJ, Widenfelt E, Essex M, Hughes MD, Shapiro RL. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009, 13:360-366.
20. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539.
21. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Ryan M, Coakley P, Boffito M, Namakula R, Kalemeera F, Colebunders R, Back D, Khoo S, Merry C. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother 2011, 66(1):180-3.
22. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001, 41:815-850.
23. Zhou X, Barber WH, Moore CK, Tee LY, Aru G, Harrison S, Mangilog B, McDaniel DO. Frequency distribution of cytochrome P450 3A4 gene polymorphism in ethnic populations and in transplant recipients. Res Commun Mol Pathol Pharmacol 2006, 119:89-104.